Viking Therapeutics Inc
| Fiscal year | Operating cash flow | Stock comp | Capex | Free cash flow | Net borrowing | FCFE | Shares (B) | FCF per share | Year-end price | FCF yield |
|---|---|---|---|---|---|---|---|---|---|---|
| 2016 | -0.0 | 0.0 | 0.0 | -0.0 | -0.0 | -0.0 | 0.02 | $-0.79 | $1.19 | -66.4% |
| 2017 | -0.0 | 0.0 | 0.0 | -0.0 | 0.0 | -0.0 | 0.03 | $-0.62 | $4.06 | -15.4% |
| 2018 | -0.0 | 0.0 | 0.0 | -0.0 | 0.0 | -0.0 | 0.06 | $-0.37 | $7.65 | -4.8% |
| 2019 | -0.0 | 0.0 | 0.0 | -0.0 | 0.0 | -0.0 | 0.07 | $-0.40 | $8.02 | -4.9% |
| 2020 | -0.0 | 0.0 | 0.0 | -0.0 | 0.0 | -0.0 | 0.07 | $-0.38 | $5.63 | -6.8% |
| 2021 | -0.0 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.08 | $-0.70 | $4.60 | -15.1% |
| 2022 | -0.0 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.08 | $-0.74 | $9.40 | -7.9% |
| 2023 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.09 | $-0.96 | $18.61 | -5.1% |
| 2024 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.11 | $-1.08 | $40.24 | -2.7% |
| 2025 | -0.3 | 0.0 | 0.0 | -0.3 | 0.0 | -0.3 | 0.11 | $-2.84 | $35.18 | -8.1% |
| 9-yr CAGR | n/m | 41.5% | n/m | n/m | n/a | n/m | 24.0% | n/m | 45.7% | avg -13.7% |
| Fiscal year | Revenue | EBITDA | EBITDA margin | Debt incl. leases | Cash & securities | Market cap | Enterprise value | EV / EBITDA | Net debt / EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| 2016 | 0.0 | -0.0 | n/m | 0.0 | 0.0 | 0 | 0 | n/m | n/m |
| 2017 | 0.0 | -0.0 | n/m | 0.0 | 0.0 | 0 | 0 | n/m | n/m |
| 2018 | 0.0 | -0.0 | n/m | 0.0 | 0.3 | 0 | 0 | n/m | n/m |
| 2019 | 0.0 | -0.0 | n/m | 0.0 | 0.3 | 1 | 0 | n/m | n/m |
| 2020 | 0.0 | -0.0 | n/m | 0.0 | 0.2 | 0 | 0 | n/m | n/m |
| 2021 | 0.0 | -0.1 | n/m | 0.0 | 0.2 | 0 | 0 | n/m | n/m |
| 2022 | 0.0 | -0.1 | n/m | 0.0 | 0.2 | 1 | 1 | n/m | n/m |
| 2023 | 0.0 | -0.1 | n/m | 0.0 | 0.4 | 2 | 1 | n/m | n/m |
| 2024 | 0.0 | -0.2 | n/m | 0.0 | 0.9 | 4 | 3 | n/m | n/m |
| 2025 | 0.0 | -0.4 | n/m | 0.0 | 0.7 | 4 | 3 | n/m | n/m |
| 9-yr CAGR | n/m | n/m | avg n/m | n/m | 55.7% | 80.6% | 100.5% | median n/m | avg n/m |
Revenue grew n/m a year and EBITDA n/m a year from FY2016 to FY2025, and free cash flow after stock compensation did not grow from a positive base. The share count rose 24.0% a year, so per-share figures grew more slowly than the totals. The balance sheet carried more cash than debt in every one of those years.
From the data: EBITDA was not positive in enough years to set a growth rate and an exit multiple, so there is no hurdle price. The share count moved 156% in FY2016 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis. The share count moved 60% in FY2017 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis. The share count moved 122% in FY2018 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis.
- Free cash flow is operating cash flow less stock-based compensation less capital spending. Stock comp is treated as a real cost.
- Net borrowing is the year's change in long-term debt. FCFE adds it back to free cash flow, the classic one-page definition.
- EBITDA is operating income plus depreciation and amortization. Debt includes lease obligations; cash includes short-term investments.
- Market cap uses the fiscal year-end price as traded, restated for later splits but not for dividends; enterprise value adds debt and subtracts cash.
- Share count is the yearly change in shares outstanding over the period; flat or falling clears. Cash margin is the latest free cash flow margin against its three-year average; within two points clears.
- Hurdle price is the present value, at the hurdle rate, of ten years of modeled free cash flow per share plus a year-10 sale at the exit multiple. It is shown as an exhibit: the 2011 to 2021 back-test found that buying below it did not sort winners from losers, so it is not scored.
- Cleared on a check means the number clears the stated rule; Not cleared means it does not. Durable, Holding and First year say how many fiscal years running the company has cleared all four staying-power checks (four or more, two or three, one); Partial and Not cleared count the checks it clears today. All of it is fact about the filings, not a rating of the stock.